Therefore, substantial revenue opportunity for conventional disease-modifying antirheumatic drugs (DMARDs) remains in early lines of therapy.
因此,在早期治疗中,常规抗风湿性关节炎疾病缓解用药还有很大市场。
Therefore, substantial revenue opportunity for conventional disease-modifying antirheumatic drugs (DMARDs) remains in early lines of therapy.
因此,在早期治疗中,常规抗风湿性关节炎疾病缓解用药还有很大市场。
应用推荐